Ken Tarkoff

Mar 15, 2017

Syapse has appointed Ken Tarkoff as its CEO. Tarkoff was chief operating officer for RelayHealth and served as senior vice president and general manager of the firm after it was acquired by McKesson. Before his time at RelayHealth, Tarkoff served as director of supplier services at Xign Corporation. He has also served as vice president of product management at Questium and vice president of regional operations at Vivra Specialty Partners.

More Like This

Jan 14, 2019

Jack Frausing

US BioTek Laboratories announced the appointment of Jack Frausing as president and CEO. Frausing assumes the leadership role from co-founder and current president Raymond Suen and his co-founder and wife Margaret Suen, the current executive vice president. The addition of Frausing is the first step in a plan to expand the company's testing and reporting capabilities and expand sales and marketing to reach and service a growing customer base. Raymond and Margaret Suen will continue to be active in the company to facilitate a smooth transition.

Jan 09, 2019

William Finger

Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.

Jan 08, 2019

Ian Heynen

Ian Heynen has been named general manager of Sysmex Canada, a wholly owned subsidiary of Sysmex America. He will execute the firm's business strategy in the Canadian market and will report to Sysmex Canada CEO Andy Hay. Heynen was most recetly senior vice president of sales and marketing for Profound Medical. Prior to that he was acting president of the international division of Hologic. 

Jan 07, 2019

Samar Parikh

Binx Health has appointed Samar Parikh to its board of directors. Parikh has held various leadership positions at Amazon including global leader business development and strategy, and general manager CPG, consumer healthcare, and consumer healthcare innovation. Boston-based Binx is developing a desktop point-of-care platform called Io to perform rapid PCR-based detection in 30 minutes and with laboratory quality results. A multicenter, clinical study is currently underway to evaluate Io for clearance from the US Food and Drug Administration for chlamydia and gonorrhea. 

Jan 07, 2019

Cindy Perettie

Foundation Medicine, a Roche company, has appointed Cindy Perettie as its CEO effective Feb. 4, replacing Troy Cox. Most recently, Perettie served as senior VP in global oncology product strategy at Roche's oncology unit. Prior to Roche, she acted as president of global development innovations at the Sarah Cannon Research Institute. Perettie has also held a number of positions at Genentech, also a unit of Roche, including VP of global regulatory operations and regional head of Europe, Middle East, and Africa operations and global development.

Jan 07, 2019

Jon Cohen, Geoff Monk

Opko Health announced the appointment of Jon Cohen as executive chairman of BioReference Laboratories. Cohen spent 10 years at Quest Diagnostics in senior executive roles, most recently as senior vice president and group executive, diagnostic solutions. Prior to joining Quest, Cohen was a managing director of health industries services at PricewaterhouseCoopers. Earlier, he served as chief medical officer at North Shore-Long Island Jewish Health System (now Northwell Health), and as chief policy advisor to New York Governor David Paterson.

The company also announced the promotion of Geoff Monk to president of BioReference Laboratories. Monk will report to Cohen. Monk joined BioReference last May as general manager.

Jan 04, 2019

Christine Tsingos

Christine Tsingos intends to retire as Executive Vice President and Chief Financial Officer of Bio-Rad, effective April 30, 2019. She has served as CFO for 16 years, during which time the company increased its revenues more than 240 percent and saw an appreciation in its stock price from approximately $30 to a recent high of more than $300 per share. Tsingos will remain in her current role through April 30, and will assist in the transition to a successor.

Jan 03, 2019

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its president and CEO. In addition, she will join the firm's board of directors. Hanna succeeds Lawrence LaPointe as CEO, who will transition to the new role of chief innovation officer and serve as an advisor to the board. Hanna previously served as Clinical Genomics' chief commercial officer. Before that, she served as president and COO at Origin. Prior to Origin, Hanna held leadership positions at Johnson & Johnson Diagnostics, where she served as VP, strategic marketing as well as VP Europe, Mideast and Africa. 

Jan 02, 2019

Steve Chapman, Robert Schueren, Matthew Rabinowitz

Natera has appointed Steve Chapman to CEO. He will take over from Matthew Rabinowitz, who will serve as executive chairman, effective Jan. 2, 2019. Chapman was previously the company's chief operating officer and Robert Schueren will replace Chapman as Natera's COO, effective Jan. 7, 2019. Schueren was most recently CEO of IntegenX, which was acquired by Thermo Fisher Scientific. Previously, he was general manager of genomics at Agilent Technologies and has also held various roles at Genentech.

Jan 02, 2019

Peter Meldrum

Myriad Genetics' former CEO Peter Meldrum passed away on Dec. 20, 2018, at the age of 71.


Meldrum co-founded Myriad in 1992 with Mark Skolnick, and led the company through many milestones, including its public offering in 1995, the launch of the flagship BRACAnalysis test, the acquisitions of Myriad RBM and Crescendo Bioscience, and the firm's expansion outside the US. By the time he retired in 2015, Myriad had grown to employ 2,500 people and had performed more than 2 million genetic tests.

After his retirement, Meldrum was the executive director of The Meldrum Foundation, his family's private charitable foundation that supports educational, artistic, and humanitarian programs. He was also chairman of the board of directors for Golden Pine Ventures, a biotech-focused venture capital firm.

Meldrum was born in 1947 in Salt Lake City, Utah. In 1970, he received his Bachelor of Science degree in chemical engineering from the University of Utah, and four years later received his MBA from the same institution. Westminster College awarded him an honorary Doctorate of Science in 2004 and the University of Utah gave him an honorary Doctorate of Engineering degree in 2009. Scientific American in 2002 selected him as one of the Top 50 Scientific Visionaries in the World.

Dec 26, 2018

Gary Huff

Gary Huff is leaving Laboratory Corporation of America, the company said in a regulatory filing on Dec. 21. Huff had been CEO of LabCorp Diagnostics. The firm said that it and Huff agreed that his "employment with the company would terminate effective Dec. 31, 2018." LabCorp gave no reason for his departure. LabCorp Chairman and CEO David King will become CEO of LabCorp Diagnostics on an interim basis. 

Dec 21, 2018

Edward Dodson, Peter Wilkinson

Laboratory Corporation of America announced that Edward Dodson, the company's senior vice president and chief accounting officer, will retire, effective April 1, 2019.  Peter Wilkinson will join the company on January 2 as senior vice president, accounting, and will assume the role of chief accounting officer upon Dodson's retirement. Wilkinson was previously executive vice president and chief financial officer of Syneos Health's clinical division. Prior to that he held several roles in the finance department of INC Research, a predecessor to Syneos, including chief accounting officer. Earlier in his career he was a financial and accounting officer at Pharmaceutical Product Development.

Dec 18, 2018

Jessica Hassel, Aurélien Marabelle

Protagen has appointed Jessica Hassel and Aurélien Marabelle to the firm's scientific advisory board. The members will support the company in developing and implementing its immuno-profiling technology. Hassel is currently the head of dermato-oncology at Germany's National Center for Tumor Disease. She has worked at the German Cancer Research Center Heidelberg, with a focus on translational oncology. Marabelle is currently the clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. He works as a senior medical oncologist and an investigator in the center's drug development department. 

Dec 17, 2018

Amy Abernethy

Amy Abernethy, current chief medical officer, CSO, and senior VP of oncology at Flatiron Health, will join the US Food and Drug Administration as principal deputy commissioner, second to the agency's commissioner Scott Gottlieb. She is slated to join the agency in early 2019, pending ethics clearances, and will replace Rachel Sherman, who is retiring as the FDA's current principal deputy commissioner. Patrizia Cavazzoni, who is deputy director for operations at the FDA's drug center, will step in as interim principal deputy commissioner till Abernethy joins.

Abernethy became an executive at cancer-focused health technology firm Flatiron more than four years ago. She currently serves as a member of the board for CareDx, and will step down from that post effective Jan. 31, 2019. She has served as a director on the company's board since July 2018 as chairman of the scientific committee. Abernethy has also worked at Athenahealth and directed the Duke Center for Learning Health Care. In an internal email about Abernethy's hire, the FDA highlighted that she is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, patient-reported outcomes, and patient-centered care, and has authored more than 400 peer-reviewed articles.

The non-profit advocacy organization Personalized Medicine Coalition, where Abernethy serves as a board member, noted in a statement that the agency's decision to hire her reflects its increasing focus on personalized medicine. While Abernethy was at Flatiron, the company struck up a research alliance with the FDA to explore how real-world data, derived from sources outside of the traditional clinical trial setting, could be used to gather evidence on the safety and efficacy of cancer treatments.

Dec 17, 2018

Richard Marsh, Benjamin Jackson

Richard Marsh, executive VP of Myriad Genetics, as well as its general counsel and secretary, will retire from the company effective July 1, 2019.  After serving as Myriad's general counsel for more than 16 years, Marsh has acceped the job of mission president for the Church of Jesus Christ of Latter-day Saints for the next three years.

Benjamin Jackson, currently Myriad's VP, assistant general counsel, and assistant secretary, will succeed Marsh. Jackson has been with the company since 2006 and has held positions dealing with commercial operations and intellectual property issues.